Glioblastoma multiforme classification

Jump to navigation Jump to search

Glioblastoma multiforme Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glioblastoma multiforme from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glioblastoma multiforme classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glioblastoma multiforme classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glioblastoma multiforme classification

CDC on Glioblastoma multiforme classification

Glioblastoma multiforme classification in the news

Blogs on Glioblastoma multiforme classification

Directions to Hospitals Treating Glioblastoma multiforme

Risk calculators and risk factors for Glioblastoma multiforme classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

Glioblastoma multiforme may be classified into several subtypes based on the origin (primary and secondary) and molecular alterations (classic, proneural, mesenchymal, and neural).The heterogeneity of GBM profiles leads to different treatment efficacy among patients. The therapy must be personalized to target each patient’s alterations in the molecular level. [1]

Classification

Based on the origin

Glioblastoma multiforme may be classified according to the origin into two subtypes: Primary and secondary.

Subtype of Glioblastoma multiforme Characteristic features
Primary glioblastoma multiforme
  • De novo origin
  • More aggressive
  • Occurs in older patients
Secondary glioblastoma multiforme
  • Arises from pre-existing lower grade gliomas
  • Less aggressive
  • Occurs in younger patients
  • Primary GBM is the most common form (about 95%) and arises typically de novo, within 3–6 months, in older patients.
  • Secondary GBM arises from prior low-grade astrocytomas (over 10–15 years) in younger patients.
  • Primary and secondary forms show some molecular differences.
  • The end result of both sub type is same since the same pathways are affected and respond similarly to current standard treatment.
  • Primary GBM often has amplified and mutated epidermal-growth factor receptor (EGFR) which encodes altered EGF receptor.
  • Secondary GBM has increased signaling through PDGF-A receptor.
  • Both types of mutations lead to increased tyrosine kinase receptor (TKR) activity and consequently to activation of RAS and PI3K pathways.
  • Primary and secondary GBM may be indistinguishable histologically but apparently differ in genetic and epigenetic profiles.

Based on the molecular alterations

  • the Cancer Genome Atlas (TCGA) divided GBM according to the molecular alterations into four subtypes:[1]
  1. Classic
  2. Proneural
  3. Mesenchymal
  4. Neural
  • Classical GBM is defined by aberrant EGFR amplification with astrocytic cell expression pattern and loss of chromosome 10.
  • The mesenchymal subtype is defined by NF1 and PTEN mutations, a mesenchymal expression profile and less EGFR amplification than in other GBM types.
  • The proneural subtype is characterized by PDGFRA focal amplification, TP53 and IDH1 mutations with an oligodenrocytic cell expression profile and younger presentation age.
  • The neural subtype is characterized by normal brain tissue gene expression wuth astrocytic and oligodendrocytic cell markers.
  • Most GBM tumors with IDH1 mutations have the proneural gene expression pattern but only 30% of preneural GBM has the IDH1 mutation.
  • IDH1 mutation is a reliable and definitive molecular diagnostic criterion of secondary GBM compared to clinical criteria.
  • The heterogeneity of GBM profiles leads to different treatment efficacy among patients.
  • The therapy must be personalized to target each patient’s alterations in the molecular level.

References

  1. 1.0 1.1 Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD; et al. (2010). "Integrated genomic analysis identifies clinically relevant subtypes of Glioblastoma multiforme characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1". Cancer Cell. 17 (1): 98–110. doi:10.1016/j.ccr.2009.12.020. PMC 2818769. PMID 20129251.


Template:WikiDoc Sources